Stem Cell Therapy for Diseases of Livestock Animals: An In-Depth Review

Veterinary Sciences, Journal Year: 2025, Volume and Issue: 12(1), P. 67 - 67

Published: Jan. 17, 2025

Stem cells are unique, undifferentiated that have the ability to both replicate themselves and develop into specialized cell types. This dual capability makes them valuable in development of regenerative medicine. Current stem research has widened their application therapy, drug discovery, reproductive cloning animals, models for various diseases. Although there substantial studies revealing treatment human degenerative diseases using cells, this is yet be explored livestock animals. Many species such as mastitis, laminitis, neuromuscular disorders, autoimmune diseases, some debilitating not covered completely by existing drugs can improved different types like embryonic adult induced pluripotent cells. review mainly focuses on use disease In addition mentioned, potential helpful wound healing, skin genetic disorders. article explores from sources therapy also role conservation endangered well model preparation. Moreover, future perspectives challenges associated with discussed. Overall, transformative impact sector comprehensively studied which will help researchers design work related

Language: Английский

---

Advances and clinical challenges of mesenchymal stem cell therapy

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: July 19, 2024

In recent years, cell therapy has provided desirable properties for promising new drugs. Mesenchymal stem cells are candidates developing genetic engineering and drug delivery strategies due to their inherent properties, including immune regulation, homing ability tumor tropism. The therapeutic potential of mesenchymal is being investigated cancer therapy, inflammatory fibrotic diseases, among others. attractive cellular carriers synthetic nanoparticles ability. this review, we comprehensively discuss the various non-genetic derivatives in delivery, tissue regeneration other fields. addition, current limitations challenges clinical translation, aiming identify important development areas future directions.

Language: Английский

---

Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 176, P. 116848 - 116848

Published: June 3, 2024

Liver fibrosis is an intrahepatic chronic damage repair response caused by various reasons such as alcoholic liver, fatty viral hepatitis, autoimmune diseases, etc., and closely related to the progression of liver disease. Currently, mechanisms its treatment are hot research topics in field disease remedy. Mesenchymal stem cells (MSCs) a class adult with self-renewal multidirectional differentiation potential, which can ameliorate through hepatic-directed differentiation, paracrine effects, immunomodulation. However, low inner-liver colonization rate, survival short duration intervention after cell transplantation have limited their wide clinical application. With intensive on worldwide, it has been found that MSCs MSCs-derived exosomes combined drugs shown better efficiency than utilization alone many animal models fibrosis. In this paper, we review interventional effects mesenchymal alleviate hepatic vivo recent years, will provide new ideas improve efficacy treating clinic.

Language: Английский

---

Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis

Stem Cell Research & Therapy, Journal Year: 2023, Volume and Issue: 14(1)

Published: Oct. 20, 2023

Abstract Aim Although the efficacy and safety of mesenchymal stem cell therapy for liver cirrhosis have been demonstrated in several studies. Clinical cases patients with are limited these studies lack consistency treatment effects. This article aimed to systematically investigate cells cirrhosis. Method The data source included PubMed/Medline, Web Science, EMBASE, Cochrane Library, from inception May 2023. Literature was screened by PICOS principle, followed literature quality evaluation assess risk bias. Finally, each study's outcome indicators were extracted a combined analysis. Outcome assessment functions adverse events. Statistical analysis performed using Review Manager 5.4. Results A total 11 clinical trials met selection criteria. pooled analysis' findings that both primary secondary had improved. Compared control group, infusion significantly increased ALB levels 2 weeks, 1 month, 3 months, 6 decreased MELD score according subgroup random-effects model. Additionally, hepatic arterial injection favored improvements levels. Importantly, none indicated any severe Conclusion results showed effective safe cirrhosis, improving function (such as decrease an increase levels) exerting protective effects on complications incidence hepatocellular carcinoma. informative treatment, large number high-quality randomized controlled validations still needed.

Language: Английский

---

Mesenchymal Stromal Cells: New Generation Treatment of Inflammatory Bowel Disease

Journal of Inflammation Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 3307 - 3334

Published: May 1, 2024

Abstract: Inflammatory bowel disease (IBD) is a chronic inflammatory of the gastrointestinal tract, which has high recurrence rate and incurable due to lack effective treatment. Mesenchymal stromal cells (MSCs) are class pluripotent stem that have recently received lot attention their strong self-renewal ability immunomodulatory effects, large number experimental clinical models confirmed positive therapeutic effect MSCs on IBD. In preclinical studies, MSC treatment for IBD relies paracrine cell-to-cell contact, its mediated mitochondrial transfer immune regulation. It also plays role in restoring intestinal mucosal barrier through homing effect, regulation microbiome, repair epithelial cells. latest trials, safety efficacy been by transfusion autologous or allogeneic bone marrow, umbilical cord, adipose MSCs, as well derived extracellular vesicles. However, regarding stable use several concerns emerge, including cell sources, management (dose, route frequency administration, pretreatment MSCs) adverse reactions. This article comprehensively summarizes effects mechanisms advantages over conventional drugs, trial progress The current challenges future directions discussed. review would add knowledge into understanding applying MSCs. Keywords: mesenchymal cells, immunomodulation, disease, ulcerative colitis, Crohn's therapy

Language: Английский

---

Therapeutic potential of mesenchymal stem cell‐derived extracellular vesicles: A focus on inflammatory bowel disease

Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(11)

Published: Nov. 1, 2024

Abstract Background Mesenchymal stem cell‐derived extracellular vesicles (MSC‐EVs) have emerged as key regulators of intercellular communication, orchestrating essential biological processes by delivering bioactive cargoes to target cells. Available evidence suggests that MSC‐EVs can mimic the functions their parental cells, exhibiting immunomodulatory, pro‐regenerative, anti‐apoptotic, and antifibrotic properties. Consequently, represent a cell‐free therapeutic option for patients with inflammatory bowel disease (IBD), overcoming limitations associated cell replacement therapy, including non‐immunogenic nature, lower risk tumourigenicity, cargo specificity ease manipulation storage. Main Topics Covered This review aims provide comprehensive examination efficacy in IBD, focus on mechanisms action potential impact treatment outcomes. We examine advantages over traditional therapies, discuss methods isolation characterisation, present mechanistic insights into effects through transcriptomic, proteomic lipidomic analyses MSC‐EV cargoes. also available preclinical studies demonstrating reduce inflammation, promote tissue repair restore intestinal homeostasis IBD models, compare these findings those clinical trials. Conclusions Finally, we highlight novel therapy identify challenges opportunities translation practice. Highlights The source mesenchymal cells (MSCs) strongly influences composition function MSC‐derived (EVs), affecting potential. Adipose‐derived MSC‐EVs, known immunoregulatory properties isolation, show promise (IBD). MicroRNAs are consistently across types involved pathways dysregulated making them agents. For example, miR‐let‐7a is inhibition apoptosis, miR‐100 supports survival, miR‐125b helps suppress pro‐inflammatory cytokines miR‐20 promotes anti‐inflammatory M2 macrophage polarisation. Preclinical models shown inflammation suppressing mediators (e.g., TNF‐α, IL‐1β, IL‐6) increasing factors IL‐4, IL‐10). They mucosal healing strengthen integrity gut barrier, suggesting address pathology.

Language: Английский

---

Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Aug. 4, 2022

Inflammatory bowel diseases (IBDs) represent a group of chronic inflammatory disorders the gastrointestinal (GI) tract including ulcerative colitis (UC), Crohn’s disease (CD), and unclassified IBDs. The pathogenesis IBDs is related to genetic susceptibility, environmental factors, dysbiosis that can lead dysfunction immune responses dysregulated homeostasis local mucosal tissues characterized by severe tissue damage in GI tract. To date, extensive studies have indicated cannot be completely cured easy relapse, thus prompting researchers find novel more effective therapeutics for this disease. Due their potent multipotent differentiation immunomodulatory capabilities, mesenchymal stem/stromal cells (MSCs) not only play an important role regulating but also display therapeutic effects on various diseases, IBDs, both preclinical clinical studies. In review, we present comprehensive overview pathological mechanisms, currently available therapeutics, particularly, potential application MSCs-based regenerative therapy

Language: Английский

---

Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: Current perspectives and future challenges

Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 253, P. 108563 - 108563

Published: Nov. 26, 2023

Language: Английский

---

Mesenchymal stromal/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications

Cell & Bioscience, Journal Year: 2023, Volume and Issue: 13(1)

Published: Sept. 5, 2023

Abstract Liver disease is a leading cause of mortality and morbidity that rising globally. dysfunctions are classified into acute chronic diseases. Various insults, including viral infections, alcohol or drug abuse, metabolic overload, may inflammation fibrosis, to irreversible liver dysfunction. Up now, transplantation could be the last resort for patients with end-stage disease. However, still faces unavoidable difficulties. Mesenchymal stromal/stem cells (MSCs) their broad ranging anti-inflammatory immunomodulatory properties can effectively used treating diseases but without limitation associated transplantation. In this review, we summarize discuss recent advances in characteristics MSCs potential action mechanisms MSCs-based cell therapies We also draw attention strategies potentiate therapeutic through pre-treatments gene modifications. Finally, progress toward clinical application extracellular vesicles

Language: Английский

---

Human umbilical cord mesenchymal stem cells inhibit liver fibrosis via the microRNA-148a-5p/SLIT3 axis

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 125, P. 111134 - 111134

Published: Oct. 31, 2023

Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have garnered considerable attention as prospective modalities of treatment for liver fibrosis (LF). The inhibition hepatic stellate cell (HSC) activation underlies the anti-fibrotic effects hUC-MSCs. However, precise mechanism by which hUC-MSCs impede HSC remains unclarified. We aimed to elucidate intrinsic mechanisms underlying therapeutic in LF patients.Mice with cirrhosis induced carbon tetrachloride (CCl4) were used experimental models and administered via tail-vein injection. alterations inflammation evaluated through histopathological examinations. RNA sequencing (RNA-seq) bioinformatics analysis then conducted investigate Finally, an in-vitro experiment involving co-cultivation or hUC-MSC-derived exosomes (MSC-Exos) LX2 was performed validate potential hepatoprotective patients.hUC-MSC therapy significantly improved function alleviated CCl4-induced mice. High-throughput RNA-Seq identified 1142 differentially expressed genes that potentially involved mediating These play important role regulating extracellular matrix. miRNA expression data (GSE151098) indicated miR-148a-5p level downregulated samples, but restored following hUC-MSC treatment. delivered exosome pathway, upregulated suppressed activated phenotype cells. SLIT3 within pool target regulated miR-148a-5p. Furthermore, administration miR-148a-5p, played a crucial suppressing SLIT3, thereby palliating fibrosis.hUC-MSCs inhibit HSCs miR-148a-5p/SLIT3 pathway are thus capable alleviating LF.

Language: Английский

---